CDKN2A and cancer: In cancer cells, the MTAP gene is frequently co-deleted with CDKN2A, and this results in MTA-mediated inhibition of the methyltransferase PRMT5; in line with this, the sensitivity to PRMT5 inhibitors is higher in cells with increased MTA levels33–35.